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ABSTRACT: For decades intensive husbandry has more or less been based on the use of antibiotics 
in sub-minimum inhibitory concentrations (sub-MIC) aimed at growth promotion. Continuous exposure 
of animal intestinal microbiota, including opportunistic zoonotic pathogens, to sub-MIC poses a 
pressure to selection and spread of bacteria strains with developed mechanism of antibiotic 
resistance. These bacteria may be transferred to people either by direct contact with farm animals or 
indirectly, via the food chain. Although in the EU a ban on the use of antibiotics as growth promoters 
was imposed in 2006, in many countries, including the largest producers and consumers of antibiotics 
in the world, it has yet to be done. Given that we are faced with a global problem of the loss of the 
efficacy of several antibiotic classes which are available for the treatment of human bacterial 
infections, it is unacceptable that antibiotic use in husbandry is not under global control. Reduction in 
antibiotic use in clinical practice in human medicine remains in dispute, but non-therapeutic use in 
husbandry remains a field in which much can be done to contribute substantially to the extension of 
antibiotic effectiveness and health care of future generations.  
 




The discovery of antibiotics is one of the 
greatest successes in medicine, which 
enabled the cure of infectious diseases 
and preserved millions of human lives. 
However, not much time has passed 
between the beginning of their use, and 
the emergence of resistance in bacteria, 
even Alexander Fleming, 70 years ago, 
warned that it would happen in a short 
time (Calderone, 2015). Researchers 
make considerable efforts to produce no-
vel classes of antibiotics, but with rapid 
evolution of resistance factors bacteria 
have an advantage in this race. For 
example, Acinetobacter baumannii, an 
opportunistic human pathogen, evolved in 
30 years from a bacterium species sus-
ceptible to all antibiotics into the one which 
has a genomic island of 45 resistance 
genes which it acquired from various ge-
nera of bacteria by horizontal transfer 
(Foumier et al., 2006). Nowadays, the situ-
ation concerning antimicrobial resistance 
is alarming and points to the entry into a 
post-antibiotic era.  
The hospital environment is a major selec-
tive environment of antibiotic-resistant ba-
cteria, which has clearly been confirmed in 
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clinical practice. The use of antibiotics is of 
huge importance in human health pro-
tection, although not necessarily justi-
fiable. It is estimated that approximately 
50% of antibiotics used in US hospitals 
was not essential, as well as that about 
45% of prescribed antibiotics were aimed 
for illnesses that antibiotics cannot help 
(Calderone, 2015). Even more worrying is 
the fact that the same or similar antibiotics 
are used in vast quantities in food-pro-
ducing animals and agriculture. In 
addition, intensive animal farming has 
mainly been based on continuous anti-
biotic administration in subtherapeutic do-
ses as growth promoters, to increase feed 
efficiency, and in disease prevention (Ka-
tsunuma et al., 2007; Modi et al., 2011; 
Schmieder and Edwards, 2012; Wang and 
Yu, 2012). This practice has been main-
tained in many countries despite the fact 
that repeated exposure of bacteria to sub-
minimum inhibitory concentrations was 
identified as a key factor which induces 
resistance (Kemper, 2008; EMEA, 1999; 
Ambrožič Avguštin, 2012). More than half 
of the total annual antibiotic production in 
the US and some other countries is spent 
in food-animal production (Wang and Yu, 
2012), and as much as 60-80% of the total 
is used for non-therapeutic purposes 
(Chapin et al., 2005). Excessive use of 
antibiotics in animal husbandry is con-
nected to high risks of the selection, 
spread and the persistence of anti-
microbial-resistant bacteria. The conse-
quences are the transfer of multiple-re-
sistant bacteria to people in farms and 
slaughterhouses or indirectly, via the food 
chain and the spread in the ecosystem, 
water and soil (Landers et al. 2012; Wang 
and Yu, 2012; Zhu et al. 2013; Wichmann 
et al. 2014).The ultimate consequence is 
the loss of antibiotic efficacy against bac-
teria with multiple resistances to antibiotics 
and ’pan-resistant’ gram-negative strains 
(Livermore, 2004; Nikaido, 2009). Only in 
the US, antibiotic-resistant bacteria cause 
more than 2 million illnesses and at least 
23,000 deaths each year (FDA, 2016). 
The Chancellor of the Exchequer UK, 
George Osborne, claimed that ’resistance 
to antibiotics will become an even greater 
threat to mankind than cancer’ explaining 
that even 10 million people could die 
worldwide each year by 2050, as a result 
of ineffective antibiotic therapy (Hughes, 
2016). 
In this paper the consequences of deploy-
ment of antibiotics as growth promoters 
are discussed when taking into conside-
ration the development of resistance in 
zoonotic bacteria and the health protection 
of people and domestic animals.   
USE OF ANTIBIOTICS AS GROWTH 
PROMOTERS IN FOOD-PRODUCING 
ANIMALS 
Historical data and mechanisms of 
action 
The use of antibiotics in subtherapeutic 
concentrations as growth promoters, was 
approved of in the 1950s (Becker, 2010; 
Schmieder and Edwards, 2012). Several 
antibiotic classes have been used as 
growth promoters: penicillins, macrolides, 
sulphonamides, tetracyclines, pleuromuti-
lins, polypeptides, streptogramins, carba-
dox, bambermycin (Becker, 2010). Pe-
nicillins and tetracyclines were the first to 
be used as feed supplements in swine, 
poultry and beef cattle in concentrations 
which correspond to 10% or 1% of the-
rapeutic doses (EMEA, 1999; Marshall 
and Levy, 2011). Tetracycline, chlor-
tetracycline and oxytetracycline are most 
frequently used in poultry, and ampicillin, 
bacitracin, erythromycin, lincomycin, virgi-
niamycin and tetracycline in swine pro-
duction (Chapin et al., 2005; Abrožič Av-
guštin, 2012). 
It has been proven in practice that the ad-
dition of antibiotics to feed for animals 
increases animal weight gains and feed 
utilisation efficacy (EMEA, 1999). The ave-
rage weight gain may increase by 4-8% 
and feed utilisation by 2-5% (Butaye et al., 
2003). The precise mechanisms of action 
of antibiotics as growth stimulators have 
yet to be completely elucidated (Becker, 
2010). However, the influence of the gas-
trointestinal (GI) microbiota undoubtedly 
plays a vital role in the process. In mono-
gastric animals the GI tract is usually colo-
nised by 400 to 500 different bacterial spe-
cies, primarily obligate anaerobes such as 
the members of genera of Bacteroides, 
Bifidobacterium and Clostridium, but also 
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some aerobes and facultative anaerobes 
(lactobacilli, streptococci, Escherichia coli) 
(Richards et al., 2005). The number of 
bacteria increases along the GI tube: in 
the proximal parts there are 103-105 CFU 
per gram of digesta and in the colonic 
contents as many as 1010-1012 CFU g-1 
(Richards et al. 2005; Dibner and Ri-
chards, 2005). The composition of micro-
biota varies depending on the animal spe-
cies and age, but is not entirely known due 
to the presence of uncultivable species. GI 
microbiota performs important functions in 
the metabolic processes, synthesis of 
short-chain fatty acids and essential 
vitamins (B and K), and influences the 
health and performance of the mono-
gastric animal host (Richards et al., 2005; 
Dibner and Richards, 2005).  
The proportion of GI bacteria to the num-
ber of host gut cells is 10:1 on average, 
which is why GI microbiota competes with 
the host cells in feed utilisation. Thus, oral 
administration of antibiotics and a conse-
quent reduction in the number of bacteria 
result in more feed components available 
to the host. In addition, research has sug-
gested that in germ-free animals the ab-
sorption of amino acids is twice the normal 
extent (Visek, 1978). The reduction of in 
bacteria number leads to increased utilisa-
tion of fat ingested with feed because of 
the intestinal bacteria catabolise bile salts, 
which results in decreased fat digestibility 
(Richards et al., 2005; Modi et al., 2011). 
Some of the metabolic products of GI 
microbiota are toxic compounds, such as 
ammonia, amines, phenols and indole, 
which all may stunt animal growth. More-
over, microbiota contributes to the thicke-
ning of the lamina propria in the gut wall 
and the length of the villi, which decrease 
nutrient digestibility (Anderson et al., 1999; 
Gaskins et al., 2002; Richards et al., 2005; 
Dibner and Richards, 2005; Modi et al., 
2011).  
In addition, bacterial antigenic determi-
nants continually encourage local immune 
response and the production of immuno-
globulins (IgA and IgG), which utilises pro-
teins necessary for growth. It is estimated 
that a human adult secretes more than 5g 
of IgA each day, which binds to GI bac-
teria and food antigens; there is no reason 
to not suppose that an analogy can be 
drawn with the adult pig (Richards et al., 
2005). Bacteria also stimulate mucus 
secretion by intestinal goblet cell and the 
turnover rates of the epithelial cells. 
The drawback of this practice is in con-
nection with the fact that GI microbiota is 
one of the most powerful non-specific 
protective mechanisms against infections, 
known as colonisation resistance (EMEA, 
1999), or competitive exclusion (Richards 
et al., 2005). Continuous oral antibiotic ad-
ministration, especially those which are 
non-absorbable or broad-spectrum, does 
irreversible damage to GI microbiota. 
Thus, animals highly susceptible to in-
fections are recruited. If the antibiotic 
treatment is ceased, these animals usually 
contract infective diseases, chickens 
especially necrotic enteritis, and pigs E. 
coli and Lawsonia intracellularis colitis 
(Marshall and Levy, 2011; Casewell et al., 
2003). Having considered these claims, it 
seems almost paradoxical that the prin-
cipal reason which supports the con-
tinuation of antibiotic use as growth pro-
moters it is stated that otherwise the use 
of antibiotics for therapeutic purposes will 
follow inevitably. In states where an-
tibiotics are still in use as growth sti-
mulators researchers suggest that the 
benefits from the prohibition of these for 
this purpose must be carefully weight 
against the consequences (Katsunuma et 
al., 2007).  
Denmark is a state where the most 
accurate data on the antibiotic expen-
diture in food animals are gathered, thanks 
to the Integrated Antimicrobial Resistance 
Monitoring and Research Programme 
(DANMAP). Research conducted from 
1992 to 2008 indicated that despite a tran-
sient increase in antibiotic deployment for 
therapeutic uses in swine, no persistent 
consecutive negative effects of the ceased 
antibiotic feed supplementation have been 
observed (Aarestrup et al., 2010). 
 Moreover, no increase in the mortality of 
poultry occurred due to necrotic enteritis, 
but the use of salinomycin was on in-
crease, which is an anticoccidial active 
against Clostridium perfringens (Dibner 
and Richards, 2005). 
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clinical practice. The use of antibiotics is of 
huge importance in human health pro-
tection, although not necessarily justi-
fiable. It is estimated that approximately 
50% of antibiotics used in US hospitals 
was not essential, as well as that about 
45% of prescribed antibiotics were aimed 
for illnesses that antibiotics cannot help 
(Calderone, 2015). Even more worrying is 
the fact that the same or similar antibiotics 
are used in vast quantities in food-pro-
ducing animals and agriculture. In 
addition, intensive animal farming has 
mainly been based on continuous anti-
biotic administration in subtherapeutic do-
ses as growth promoters, to increase feed 
efficiency, and in disease prevention (Ka-
tsunuma et al., 2007; Modi et al., 2011; 
Schmieder and Edwards, 2012; Wang and 
Yu, 2012). This practice has been main-
tained in many countries despite the fact 
that repeated exposure of bacteria to sub-
minimum inhibitory concentrations was 
identified as a key factor which induces 
resistance (Kemper, 2008; EMEA, 1999; 
Ambrožič Avguštin, 2012). More than half 
of the total annual antibiotic production in 
the US and some other countries is spent 
in food-animal production (Wang and Yu, 
2012), and as much as 60-80% of the total 
is used for non-therapeutic purposes 
(Chapin et al., 2005). Excessive use of 
antibiotics in animal husbandry is con-
nected to high risks of the selection, 
spread and the persistence of anti-
microbial-resistant bacteria. The conse-
quences are the transfer of multiple-re-
sistant bacteria to people in farms and 
slaughterhouses or indirectly, via the food 
chain and the spread in the ecosystem, 
water and soil (Landers et al. 2012; Wang 
and Yu, 2012; Zhu et al. 2013; Wichmann 
et al. 2014).The ultimate consequence is 
the loss of antibiotic efficacy against bac-
teria with multiple resistances to antibiotics 
and ’pan-resistant’ gram-negative strains 
(Livermore, 2004; Nikaido, 2009). Only in 
the US, antibiotic-resistant bacteria cause 
more than 2 million illnesses and at least 
23,000 deaths each year (FDA, 2016). 
The Chancellor of the Exchequer UK, 
George Osborne, claimed that ’resistance 
to antibiotics will become an even greater 
threat to mankind than cancer’ explaining 
that even 10 million people could die 
worldwide each year by 2050, as a result 
of ineffective antibiotic therapy (Hughes, 
2016). 
In this paper the consequences of deploy-
ment of antibiotics as growth promoters 
are discussed when taking into conside-
ration the development of resistance in 
zoonotic bacteria and the health protection 
of people and domestic animals.   
USE OF ANTIBIOTICS AS GROWTH 
PROMOTERS IN FOOD-PRODUCING 
ANIMALS 
Historical data and mechanisms of 
action 
The use of antibiotics in subtherapeutic 
concentrations as growth promoters, was 
approved of in the 1950s (Becker, 2010; 
Schmieder and Edwards, 2012). Several 
antibiotic classes have been used as 
growth promoters: penicillins, macrolides, 
sulphonamides, tetracyclines, pleuromuti-
lins, polypeptides, streptogramins, carba-
dox, bambermycin (Becker, 2010). Pe-
nicillins and tetracyclines were the first to 
be used as feed supplements in swine, 
poultry and beef cattle in concentrations 
which correspond to 10% or 1% of the-
rapeutic doses (EMEA, 1999; Marshall 
and Levy, 2011). Tetracycline, chlor-
tetracycline and oxytetracycline are most 
frequently used in poultry, and ampicillin, 
bacitracin, erythromycin, lincomycin, virgi-
niamycin and tetracycline in swine pro-
duction (Chapin et al., 2005; Abrožič Av-
guštin, 2012). 
It has been proven in practice that the ad-
dition of antibiotics to feed for animals 
increases animal weight gains and feed 
utilisation efficacy (EMEA, 1999). The ave-
rage weight gain may increase by 4-8% 
and feed utilisation by 2-5% (Butaye et al., 
2003). The precise mechanisms of action 
of antibiotics as growth stimulators have 
yet to be completely elucidated (Becker, 
2010). However, the influence of the gas-
trointestinal (GI) microbiota undoubtedly 
plays a vital role in the process. In mono-
gastric animals the GI tract is usually colo-
nised by 400 to 500 different bacterial spe-
cies, primarily obligate anaerobes such as 
the members of genera of Bacteroides, 
Bifidobacterium and Clostridium, but also 
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some aerobes and facultative anaerobes 
(lactobacilli, streptococci, Escherichia coli) 
(Richards et al., 2005). The number of 
bacteria increases along the GI tube: in 
the proximal parts there are 103-105 CFU 
per gram of digesta and in the colonic 
contents as many as 1010-1012 CFU g-1 
(Richards et al. 2005; Dibner and Ri-
chards, 2005). The composition of micro-
biota varies depending on the animal spe-
cies and age, but is not entirely known due 
to the presence of uncultivable species. GI 
microbiota performs important functions in 
the metabolic processes, synthesis of 
short-chain fatty acids and essential 
vitamins (B and K), and influences the 
health and performance of the mono-
gastric animal host (Richards et al., 2005; 
Dibner and Richards, 2005).  
The proportion of GI bacteria to the num-
ber of host gut cells is 10:1 on average, 
which is why GI microbiota competes with 
the host cells in feed utilisation. Thus, oral 
administration of antibiotics and a conse-
quent reduction in the number of bacteria 
result in more feed components available 
to the host. In addition, research has sug-
gested that in germ-free animals the ab-
sorption of amino acids is twice the normal 
extent (Visek, 1978). The reduction of in 
bacteria number leads to increased utilisa-
tion of fat ingested with feed because of 
the intestinal bacteria catabolise bile salts, 
which results in decreased fat digestibility 
(Richards et al., 2005; Modi et al., 2011). 
Some of the metabolic products of GI 
microbiota are toxic compounds, such as 
ammonia, amines, phenols and indole, 
which all may stunt animal growth. More-
over, microbiota contributes to the thicke-
ning of the lamina propria in the gut wall 
and the length of the villi, which decrease 
nutrient digestibility (Anderson et al., 1999; 
Gaskins et al., 2002; Richards et al., 2005; 
Dibner and Richards, 2005; Modi et al., 
2011).  
In addition, bacterial antigenic determi-
nants continually encourage local immune 
response and the production of immuno-
globulins (IgA and IgG), which utilises pro-
teins necessary for growth. It is estimated 
that a human adult secretes more than 5g 
of IgA each day, which binds to GI bac-
teria and food antigens; there is no reason 
to not suppose that an analogy can be 
drawn with the adult pig (Richards et al., 
2005). Bacteria also stimulate mucus 
secretion by intestinal goblet cell and the 
turnover rates of the epithelial cells. 
The drawback of this practice is in con-
nection with the fact that GI microbiota is 
one of the most powerful non-specific 
protective mechanisms against infections, 
known as colonisation resistance (EMEA, 
1999), or competitive exclusion (Richards 
et al., 2005). Continuous oral antibiotic ad-
ministration, especially those which are 
non-absorbable or broad-spectrum, does 
irreversible damage to GI microbiota. 
Thus, animals highly susceptible to in-
fections are recruited. If the antibiotic 
treatment is ceased, these animals usually 
contract infective diseases, chickens 
especially necrotic enteritis, and pigs E. 
coli and Lawsonia intracellularis colitis 
(Marshall and Levy, 2011; Casewell et al., 
2003). Having considered these claims, it 
seems almost paradoxical that the prin-
cipal reason which supports the con-
tinuation of antibiotic use as growth pro-
moters it is stated that otherwise the use 
of antibiotics for therapeutic purposes will 
follow inevitably. In states where an-
tibiotics are still in use as growth sti-
mulators researchers suggest that the 
benefits from the prohibition of these for 
this purpose must be carefully weight 
against the consequences (Katsunuma et 
al., 2007).  
Denmark is a state where the most 
accurate data on the antibiotic expen-
diture in food animals are gathered, thanks 
to the Integrated Antimicrobial Resistance 
Monitoring and Research Programme 
(DANMAP). Research conducted from 
1992 to 2008 indicated that despite a tran-
sient increase in antibiotic deployment for 
therapeutic uses in swine, no persistent 
consecutive negative effects of the ceased 
antibiotic feed supplementation have been 
observed (Aarestrup et al., 2010). 
 Moreover, no increase in the mortality of 
poultry occurred due to necrotic enteritis, 
but the use of salinomycin was on in-
crease, which is an anticoccidial active 
against Clostridium perfringens (Dibner 
and Richards, 2005). 
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growth promoters and for therapeutic rea-
sons in food animals (Xiao et al., 2008).  
Antibiotics which are not used in humans, 
such as monensin, salinomycin, virginia-
mycin, tylosin, spiramycin, avilamycin, 
avoparcin, ardacin, olaquindox and car-
badox have also been used as growth 
promoters (Butaye et al., 2003).  
However, it has been confirmed that due 
to the chemical similarity of these with 
those used in humans and the fact that 
they are aimed at the same bacterial 
targets, the use of veterinary products can 
produce cross-resistance (Marshall and 
Levy, 2011). For these reasons it is 
possible to detect bacteria with resistance 
genes to antibiotics which have never 
been used in animals on a particular farm. 
The classic example is avoparcin (a 
glycopeptide), which started being used as 
feed supplement at the beginning of 1970s 
and was in use in the EU for nearly 20 
years. It led to the selection of vanco-
mycin-resistant enterococci (VRE), which 
were first detected in Europe in 1986 and 
in the following year in the USA (EMEA, 
1999). VRE strains exhibit partial cross-re-
sistance with teicoplanin (Butaye et al., 
2003).  
In people who were in direct contact with 
these animals the same clones of van-
comycin-resistant enterococci (VRE) were 
found (Stobberingh et al., 1999). A link 
between the resistance in animal and hu-
man hospital isolates of avoparcin- and 
vancomycin-coresistant Enterococcus spp. 
was also confirmed using ribotyping me-
thods (Bates et al., 1994). Multi/methi-
cillin-resistant Staphylococcus aureus and 
vancomycin-resistant enterococci (VRE) 
are the most common causes of noso-
comial infections, and the genes coding 
resistance to vancomycin can be trans-
ferred via plasmids to S. aureus (Noble et 
al., 1992).  
It is even more concerning given that 
vancomycin is the major drug for the the-
rapy of human infections caused by multi-
drug-resistant (MDR) Enterococcus and 
frequently a drug of last resort. Human in-
fection with VRE strains, especially in 
liver-transplant patients and those with he-
matologic malignancies, could be life-
threatening (Rice, 2001). 
One reasonable means of combat against 
resistance seems to be the termination of 
antibiotic use for non-therapeutic pur-
poses. The prohibition of avoparcin in the 
EU resulted in the decrease in the number 
of VRE in broilers, but not in pigs. In the 
latter, there was a clone expansion of VRE 
with resistance genes for glycopeptides 
(vanA) and macrolides (ermB) located on 
the same mobile DNA (Aarestrup, 2005). 
Moreover, two years after the decrease in 
the use of tylosin for growth promotion and 
therapy in pigs, a considerable decline in 
VRE among Enterococcus faecium iso-
lates occurred (Aarestrup, 2005). The ban 
of tylosine use in Denmark led to the de-
crease in the resistance of Enterococcus 
faecium not only to this antibiotic, but also 
to erythromycin, a chemically related ma-
crolide (DANMAP, 2008). Following the 
prohibition of avoparcin use as feed sup-
plement in Denmark (Bager et al., 1997), 
Italy (Pantosti et al., 1999), Hungary 
(Kaszanyitzky et al., 2007) and Germany 
(Klare et al., 1999), a considerable decline 
in the prevalence of vancomycin-resistant 
Enterococcus strains in poultry, pigs and 
cattle was detected. Commission of the 
EU banned avoparcin in all member states 
in 1997 (Dibner and Richards, 2005). In-
vestigation into the resistance of Ente-
rococcus from the gut microbiota of 
healthy people towards vancomycin sho-
wed decreased VRE colonisation (Klare et 
al., 1999). 
Large quantities of antibiotics used in 
intensive animal husbandry influence the 
selection of resistant bacteria in animals 
and their secretions. Given that bacteria 
account for about 50% of the faeces, the 
annual quantity of 180 million dry tons of 
livestock and poultry manure merely in the 
US represents 90 dry tons of bacteria with 
developed resistance mechanisms against 
antibiotics (Wang and Yu, 2012).  
Moreover, antibiotics used as growth 
promoters are usually poorly absorbed 
and 30-80% may be excreted as waste 
(Ambrožič Avguštin, 2012). Both anti-
biotics and resistant bacterial strains are 
spread by fertilisation to agricultural areas, 
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which is why people are indirectly exposed 
to risk of infections with resistant bacteria 
via the food chain. 
Rules and regulations 
Soon after the beginning of the use of 
antibiotics as feed supplements, the justi-
fication of this decision was questioned in 
Europe. In Denmark in 1969 the recom-
mendation of the Swann committee was 
issued, which stated that antibiotics which 
were used in therapy of infections in hu-
mans and animals should not be used as 
growth promoters (Aarestrup, 2005). In 
1969, in accordance with the recommen-
dations of the Joint Committee on the Use 
of Antibiotics in Animal Husbandry and 
Veterinary Medicine, the use of penicillin, 
tetracyclines and sulphonamides as feed 
supplements was banned in the EU, but 
macrolides such as tylosin and spiramycin 
were used in the next 30 years, despite 
the importance of erythromycin, a related 
antibiotic, for human infections (EMEA, 
1999). In 1985 in Sweden the Feeding 
Stuffs Act was issued, which was the first 
one to outlaw the use of antibiotics as 
animal growth promoters (Dibner and 
Richard, 2005).  
From 1995, avoparcin (glycopeptide) has 
been banned in animals in Denmark, and 
from 1997 in the other member countries 
of the EU (Aarestrup, 2005; Ambrožič 
Avguštin, 2012). In 1999 the EU banned 
the use of bacitracin, spiramycin, tylosin 
and virginiamycin for growth promotion 
(Katsunuma et al., 2007). From 1 January 
2006 all growth promoters have been 
banned from European agriculture by 
Regulation (EC) No 1831/2003 of the 
European Parliament and of the Council of 
22 September 2003 (Regulation (EC) No 
1831/2003; Kemper, 2008; Becker, 2010). 
In Serbia, the complete feed for animals 
must not contain antibiotics and sulfo-
namides (Pravilnik o kvalitetu hrane za 
životinje, 2010).  
However, the use of antibiotics as growth 
promoters is still a practice in many 
countries, including large drug producers 
and consumers, such as the USA, China 
and Japan. For instance, in the USA, in 
1951 a total of 100 tons of antibiotics were 
spent in animal husbandry, mostly as feed 
supplements, but 27 years later as much 
as 5,580 tons (Aarestrup, 2005). In 2009, 
80% of total antibiotics used in the US 
were spent for non-human use, and 64% 
of these were administered to healthy ani-
mals (FDA, 2014). It is estimated that in 
the US up to eight times higher quantities 
of antibiotics are used for non-therapeutic 
purposes than for animal therapy (Mar-
shall and Levy, 2011). In Australia 55.8% 
of antibiotics were used in stock feeds 
(Modi et al., 2011). China is the world’s 
largest producer and consumer of anti-
biotics and in its industrial pig farms all 
major classes of antibiotics are used as 
growth promoters or for therapeutic rea-
sons (Zhu et al., 2013). In Japan six syn-
thetic antimicrobials and 19 antibiotics are 
approved for growth promotion (Katsu-
numa et al., 2007).  
It has been claimed that the consumption 
of medically important antimicrobials ap-
proved for use in food-producing animals 
increased by 23% from 2009 to 2014 
(FDA, 2015). In May 2016, FDA requested 
from drug-producing companies precise 
data on the quantities of antibiotics used 
annually in the four major food-producing 
animal species: pigs, cattle, chickens and 
turkeys. One of the objectives of this re-
quest is to remove growth promotion as an 
approved use for antibiotics (Pew Cha-
ritable Trusts website, 2016). The goal is 
to administer antibiotics in feed only when 
medically necessary, that is, for the 
therapy of sick, and not all animals. 
In Japan in 1999 a Veterinary Antimi-
crobial Resistance Monitoring System was 
established. Its main focus is the investi-
gation into the influence of antibiotics ad-
ministered to animals via feed on the 
emergence of antimicrobial resistance, pri-
marily in Enterococcus and E. coli; the 
ultimate goal is to assess the necessity of 
the withdrawal of antibiotics as growth pro-
moters in the whole country (Katsunuma 
et al., 2007). 
In the EU experts agree that non-the-
rapeutic use of antibiotics in food-
producing animals pose a high risk to the 
development of resistance and transfer of 
multiple-resistant bacteria strains to 
people. By contrast, in some other coun-
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growth promoters and for therapeutic rea-
sons in food animals (Xiao et al., 2008).  
Antibiotics which are not used in humans, 
such as monensin, salinomycin, virginia-
mycin, tylosin, spiramycin, avilamycin, 
avoparcin, ardacin, olaquindox and car-
badox have also been used as growth 
promoters (Butaye et al., 2003).  
However, it has been confirmed that due 
to the chemical similarity of these with 
those used in humans and the fact that 
they are aimed at the same bacterial 
targets, the use of veterinary products can 
produce cross-resistance (Marshall and 
Levy, 2011). For these reasons it is 
possible to detect bacteria with resistance 
genes to antibiotics which have never 
been used in animals on a particular farm. 
The classic example is avoparcin (a 
glycopeptide), which started being used as 
feed supplement at the beginning of 1970s 
and was in use in the EU for nearly 20 
years. It led to the selection of vanco-
mycin-resistant enterococci (VRE), which 
were first detected in Europe in 1986 and 
in the following year in the USA (EMEA, 
1999). VRE strains exhibit partial cross-re-
sistance with teicoplanin (Butaye et al., 
2003).  
In people who were in direct contact with 
these animals the same clones of van-
comycin-resistant enterococci (VRE) were 
found (Stobberingh et al., 1999). A link 
between the resistance in animal and hu-
man hospital isolates of avoparcin- and 
vancomycin-coresistant Enterococcus spp. 
was also confirmed using ribotyping me-
thods (Bates et al., 1994). Multi/methi-
cillin-resistant Staphylococcus aureus and 
vancomycin-resistant enterococci (VRE) 
are the most common causes of noso-
comial infections, and the genes coding 
resistance to vancomycin can be trans-
ferred via plasmids to S. aureus (Noble et 
al., 1992).  
It is even more concerning given that 
vancomycin is the major drug for the the-
rapy of human infections caused by multi-
drug-resistant (MDR) Enterococcus and 
frequently a drug of last resort. Human in-
fection with VRE strains, especially in 
liver-transplant patients and those with he-
matologic malignancies, could be life-
threatening (Rice, 2001). 
One reasonable means of combat against 
resistance seems to be the termination of 
antibiotic use for non-therapeutic pur-
poses. The prohibition of avoparcin in the 
EU resulted in the decrease in the number 
of VRE in broilers, but not in pigs. In the 
latter, there was a clone expansion of VRE 
with resistance genes for glycopeptides 
(vanA) and macrolides (ermB) located on 
the same mobile DNA (Aarestrup, 2005). 
Moreover, two years after the decrease in 
the use of tylosin for growth promotion and 
therapy in pigs, a considerable decline in 
VRE among Enterococcus faecium iso-
lates occurred (Aarestrup, 2005). The ban 
of tylosine use in Denmark led to the de-
crease in the resistance of Enterococcus 
faecium not only to this antibiotic, but also 
to erythromycin, a chemically related ma-
crolide (DANMAP, 2008). Following the 
prohibition of avoparcin use as feed sup-
plement in Denmark (Bager et al., 1997), 
Italy (Pantosti et al., 1999), Hungary 
(Kaszanyitzky et al., 2007) and Germany 
(Klare et al., 1999), a considerable decline 
in the prevalence of vancomycin-resistant 
Enterococcus strains in poultry, pigs and 
cattle was detected. Commission of the 
EU banned avoparcin in all member states 
in 1997 (Dibner and Richards, 2005). In-
vestigation into the resistance of Ente-
rococcus from the gut microbiota of 
healthy people towards vancomycin sho-
wed decreased VRE colonisation (Klare et 
al., 1999). 
Large quantities of antibiotics used in 
intensive animal husbandry influence the 
selection of resistant bacteria in animals 
and their secretions. Given that bacteria 
account for about 50% of the faeces, the 
annual quantity of 180 million dry tons of 
livestock and poultry manure merely in the 
US represents 90 dry tons of bacteria with 
developed resistance mechanisms against 
antibiotics (Wang and Yu, 2012).  
Moreover, antibiotics used as growth 
promoters are usually poorly absorbed 
and 30-80% may be excreted as waste 
(Ambrožič Avguštin, 2012). Both anti-
biotics and resistant bacterial strains are 
spread by fertilisation to agricultural areas, 
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to risk of infections with resistant bacteria 
via the food chain. 
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spent in animal husbandry, mostly as feed 
supplements, but 27 years later as much 
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were spent for non-human use, and 64% 
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mals (FDA, 2014). It is estimated that in 
the US up to eight times higher quantities 
of antibiotics are used for non-therapeutic 
purposes than for animal therapy (Mar-
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of antibiotics were used in stock feeds 
(Modi et al., 2011). China is the world’s 
largest producer and consumer of anti-
biotics and in its industrial pig farms all 
major classes of antibiotics are used as 
growth promoters or for therapeutic rea-
sons (Zhu et al., 2013). In Japan six syn-
thetic antimicrobials and 19 antibiotics are 
approved for growth promotion (Katsu-
numa et al., 2007).  
It has been claimed that the consumption 
of medically important antimicrobials ap-
proved for use in food-producing animals 
increased by 23% from 2009 to 2014 
(FDA, 2015). In May 2016, FDA requested 
from drug-producing companies precise 
data on the quantities of antibiotics used 
annually in the four major food-producing 
animal species: pigs, cattle, chickens and 
turkeys. One of the objectives of this re-
quest is to remove growth promotion as an 
approved use for antibiotics (Pew Cha-
ritable Trusts website, 2016). The goal is 
to administer antibiotics in feed only when 
medically necessary, that is, for the 
therapy of sick, and not all animals. 
In Japan in 1999 a Veterinary Antimi-
crobial Resistance Monitoring System was 
established. Its main focus is the investi-
gation into the influence of antibiotics ad-
ministered to animals via feed on the 
emergence of antimicrobial resistance, pri-
marily in Enterococcus and E. coli; the 
ultimate goal is to assess the necessity of 
the withdrawal of antibiotics as growth pro-
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tries the relationship between the use of 
antibiotics in food-producing animals and 
drug-resistant bacteria in humans is still a 
contentious issue (Marshall and Levy, 
2011).  
CONCLUDING REMARKS 
Public health experts warn that a strict 
control or a total ban on the use of anti-
biotics as growth promoters is inevitable, 
particularly of those which are associated 
with human medical treatments. Agricul-
tural producers, however, claim that, 
firstly, without antibiotics many phases in 
animal production would not be commer-
cially sustainable, and secondly, that there 
are no sufficiently strong scientific proofs 
of the connection between the use of an-
tibiotics as growth stimulators and the 
bacterial resistance. Until a final agre-
ement is achieved, profound conse-
quences on animal health keep arising, 
the mechanisms of resistance towards an-
tibiotics are emerging and spreading 
among both commensals and pathogens, 
and these disseminate into the environ-
ment and eventually, affect human health. 
The use of antibiotics is inevitable to main-
tain domestic animals’ health, particularly 
in intensive animal production, but it can-
not act as a substitution for good hygiene 
management The termination of conti-
nuous antibiotic use requires considerable 
changes in animal husbandry manage-
ment, reduction in stock density, higher 
standards of hygiene, accurate, precise 
and timely antibiotic therapy, deployment 
of alternative substances for disease pre-
vention (such as enzymes, prebiotics, 
organic acids, probiotics, trace minerals or 
herbs) and vaccines (Kemper, 2008). 
Humans are capable only of preventing 
the emergence of additional reasons 
which may powerfully influence the in-
crease in the number and the spread of 
resistance genes in bacteria. Facing the 
danger which the diseases caused by bac-
teria strains resistant to available anti-
biotics may threaten, it is incomprehen-
sive that the use of antibiotics in ve-
terinary medicine in the majority of coun-
tries is still not under strict control. Feed 
and foods of animal origin are distributed 
across the world, which makes the re-
sistance which emerged in any country the 
problem for all (Aarestrup, 2005). Today, 
on the threshold of the post-antibiotic era, 
the use of antibiotics for non-therapeutic 
purposes is unacceptable. Still remains 
the open question when the measures for 
strict control of antibiotic use in animal 
husbandry will be taken on a global level, 
which is of utmost importance for the 
maintenance of their effectiveness and 
health protection of future generations.  
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Сажетак: Интензивна сточарска производња се деценијама у већој или мањој мери 
базира на употреби антибиотика у субинхибиторним концентрацијама за промоцију раста. 
Континуирано излагање микробиота дигестивног тракта животиња (укључујући и опор-
тунистичке зоонотске патогене) суб-инхибиторним концентрацијама антибиотика, представља 
притисак на селекцију и ширење сојева бактерија са механизмима резистенције на антибиотике. 
На људе се ове бактерије могу пренети директним контактом са фармским животињама или на 
посредан начин, преко ланца исхране. Иако је у земљама Европске уније употреба антибиотика 
за промоцију раста животиња забрањена 2006. године, у многим државама, укључујући највеће 
произвођаче и потрошаче антибиотика у свету, ова пракса се задржала до данас. Губитак 
ефикасности антибиотика који су тренутно на располагању за лечење бактеријских инфекција 
код људи је растући проблем, због чега је неприхватљиво да употреба антибиотика у сточарској 
производњи није под глобалном контролом. Клиничка пракса у хуманој медицини оставља 
дискутабилан простор за редукцију примене антибиотика, али je нетерапеутска употреба у 
сточарству област у оквиру које се може значајно допринети продужавању века 
употребљивости појединих класа антибиотика и  очувању здравља будућих генерација.  
Кључне речи: антибиотици, додаци храни, резистенција бактерија  
Received: 13 October 2016 
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